Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T12:01:29.493Z.
Calculation as of: 2026-10-06T12:01:29.493Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: cf0630fc9642b75147419b140bafddb7ccff0a2362c2d95f2dd7172ee2000ae5
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$922.50M
EV/EBIT Ratio
6.16x
TTM Avg
5.93x
3Y Avg
5.93x
5Y Avg
5.93x
Market Cap
$903.13M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$985.79M
EV/EBIT Ratio
N/A
TTM Avg
2.12x
3Y Avg
2.12x
5Y Avg
2.12x
Market Cap
$867.60M
EV/EBIT Ratio
N/A
TTM Avg
76.83x
3Y Avg
76.83x
5Y Avg
76.83x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CeriBell, Inc. (CBLL) | $943.26M | N/A | N/A | N/A | N/A |
| Arbutus Biopharma Corp (ABUS)vs › | $922.50M | 6.16x | 5.93x | 5.93x | 5.93x |
| Bioventus Inc. (BVS)vs › | $915.95M | 18.60x | 17.93x | 24.19x | 30.14x |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $903.13M | N/A | N/A | N/A | N/A |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $985.79M | N/A | 2.12x | 2.12x | 2.12x |
| Aktis Oncology, Inc. (AKTS)vs › | $989.05M | N/A | N/A | N/A | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $867.60M | N/A | 76.83x | 76.83x | 76.83x |
| Apnimed, Inc. (APMD)vs › | $866.15M | N/A | N/A | N/A | N/A |
| Beta Bionics, Inc. (BBNX)vs › | $852.55M | N/A | N/A | N/A | N/A |
| Alumis Inc. (ALMS)vs › | $844.28M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute